Sandoz Recalls Losartan Potassium and Ezetimibe Prescription Drug Bottles Due to Failure to Meet Child-Resistant Closure Requirements

What was recalled

In August 2019, the U.S. Consumer Product Safety Commission (CPSC) announced a significant recall initiated by Sandoz, a major pharmaceutical manufacturer. This action targeted specific bottles of prescription medications that failed to meet federal safety standards for child-resistant packaging. The affected products are prescription drugs containing two active ingredients: Losartan Potassium and Ezetimibe. Specifically, the recall focuses on bottles of Ezetimibe 10mg Tablets and Losartan Potassium 50mg Tablets distributed by Sandoz. These medications are commonly prescribed to help manage high blood pressure and lower cholesterol levels, meaning a substantial number of households may have been using them at the time the recall was issued.

The core issue lies not in the medication itself, which remains effective and safe for its intended purpose, but in the packaging that contains it. The recalled bottles do not possess the child-resistant closure mechanism required by the Poison Prevention Packaging Act. This legislation is designed to prevent young children from accidentally opening medication containers and ingesting pills, a scenario that can lead to severe poisoning or death. While the drugs inside are therapeutic, the failure of the bottle caps to lock securely against curious hands created an unacceptable safety gap. Consumers who purchased these specific bottles were effectively holding medication in a container that could be opened by a child with minimal effort.

The scope of this recall is defined by precise product identifiers rather than just brand names. The affected inventory includes Ezetimibe 10mg Tablets, identified by the National Drug Code (NDC) number 0781-5690-31 in 30-count bottles and NDC 0781-5690-92 in 90-count bottles. Additionally, Losartan Potassium 50mg Tablets with NDC 0781-5701-31 in 30-count bottles were included. The recall was not blanket across all Sandoz products but was strictly limited to those with specific lot numbers and expiration dates. For the Ezetimibe 30-count bottles, this included lots JE4491 through JM2258 with expiration dates ranging from August 2020 to October 2020. The 90-count Ezetimibe bottles involved were lots JE4481, JG0249, JK8989, and JN0764, with expiration dates extending into January 2021. For the Losartan Potassium, lot HV9471 with an expiration date of February 2020 was included.

To identify if you possess a recalled item, look closely at the bottle labels. The front of the label clearly displays "Sandoz," the name of the medication, the dosage strength, and the NDC number. The side of the label contains the crucial lot number and expiration date. If your bottle matches any of the lot numbers listed above, it is part of this recall. Although no incidents or injuries were reported to the CPSC at the time of the announcement, the potential for harm was significant enough to warrant immediate action. Sandoz urged consumers to check their medicine cabinets against these specific identifiers to ensure they were not using a bottle with non-compliant safety closures.

The hazard, explained

When we talk about prescription medications being recalled for packaging defects, it is easy to focus on the administrative side of things—the lot numbers, the expiration dates, and the corporate logistics. However, the core issue here is a fundamental failure in physical safety design. This specific recall by Sandoz involves bottles of Losartan Potassium and Ezetimibe where the closure mechanism does not meet the rigorous standards set by the Poison Prevention Packaging Act (PPPA). To understand why this matters, we have to look at what child-resistant packaging is actually designed to do and how its failure creates a tangible danger.

Child-resistant closures are not just "tough" caps. They are engineered with specific mechanical resistance that requires a combination of strength, dexterity, and coordinated motor skills that young children typically do not possess. The standard generally requires that the package withstands significant force from twisting or pushing while remaining closed, yet can be opened by an adult using two hands or complex manipulation. In this instance, the bottles in question failed to meet these requirements. Physically, this means the latch, screw thread, or push-and-turn mechanism is either too loose, lacks sufficient friction, or does not engage correctly. As a result, a child who might normally be unable to open a standard medicine bottle can now access the contents with relative ease—perhaps by simply pulling up on the cap or applying less torque than usual.

The danger arises from the intersection of this mechanical failure and human behavior. Most adults assume that if a medication is in its original prescription bottle, it is safe. We often place these bottles on kitchen counters, bathroom vanities, or nightstands because they are convenient for daily management of health conditions like high blood pressure or high cholesterol. We trust the "child-resistant" label implicitly. When that trust is broken by defective packaging, the barrier between a child and a potent pharmaceutical compound disappears. Ezetimibe and Losartan Potassium are not candy; they are systemic drugs that alter how the body processes cholesterol and regulates blood pressure. If a young child ingests even a small number of these tablets, their developing physiology can react severely to dosages calibrated for adults.

The specific harm in this scenario is accidental poisoning. Children are naturally curious and often explore the world by putting objects in their mouths. Without a properly functioning barrier, they may mistake the pills for sweets or simply swallow them out of curiosity. The resulting toxicity can lead to serious health complications, ranging from gastrointestinal distress and dizziness to more severe cardiovascular effects depending on the amount ingested and the child’s body weight. It is important to note that while no incidents have been reported in this specific recall, the risk is latent and present in every bottle with the affected lot numbers. The absence of a current report does not mean the hazard is minor; it simply means that, so far, parents and caregivers have either secured the medication elsewhere or caught the issue before an accident occurred.

Ultimately, this recall highlights how a small manufacturing variance in plastic molding or cap assembly can bypass critical safety layers. The "mechanism" of harm here is not chemical instability of the drug itself, but rather the accessibility of a dangerous substance to those who cannot understand its risks and lack the physical ability to safely handle it. By failing the child-resistant test, these bottles remove the last line of defense that protects children in households where prescription medications are kept for convenience.

Who is most at risk

While this recall involves prescription medications that are prescribed to a wide demographic of adults for managing blood pressure and cholesterol, the primary group at immediate physical risk from this specific packaging failure is young children. The U.S. Consumer Product Safety Commission (CPSC) initiated this alert because the bottles provided by Sandoz failed to meet the strict child-resistant closure requirements mandated by the Poison Prevention Packaging Act. This law exists for a critical reason: standard bottle caps, or even some "easy-open" caps that do not meet federal testing standards, can be opened by toddlers and young preschoolers who are naturally curious and lack the cognitive understanding of danger. Even if a child cannot fully remove the cap, they may be able to loosen it enough to spill pills or access them in ways an adult would find difficult but a determined two-year-old could manage.

The vulnerability of this hazard is compounded by the specific nature of the medications involved: Losartan Potassium and Ezetimibe. These are not vitamins or supplements; they are potent pharmaceuticals designed to alter physiological processes. For an adult, taking a prescribed dose is a routine part of health management. For a small child, however, even a single tablet can be catastrophic. Children have significantly lower body weight than adults, meaning the concentration of medication in their bloodstream after ingestion would be disproportionately high compared to a therapeutic dose. This makes accidental ingestion far more likely to result in severe poisoning, organ damage, or other life-threatening complications than it would for an adult who accidentally takes an extra pill.

Elderly individuals may also find themselves indirectly affected by this issue, not because they are at risk of poisoning from the packaging itself, but due to the confusion surrounding "easy-open" versus "child-resistant" closures. Many seniors or those with arthritis prefer caps that are easier to open. However, in this specific recall, the failure was that the bottles did *not* meet child-resistant standards, implying they may have been too easy for a child to open, rather than being too difficult for an adult. Nevertheless, any household with a child under the age of five must treat these bottles with extreme caution until the remedy is applied. The risk is not just about who takes the medicine, but who lives in the home and has access to the physical object containing the medicine. If you have young children, visitors with young children, or even older grandchildren who might mimic adult behaviors, the presence of these unsecured medication bottles creates an unnecessary and unacceptable hazard.

It is also important to note that while no incidents have been reported as of the recall date in August 2019, the potential for incident remains high because the flaw is structural. The packaging looks like a standard prescription bottle, which may lead caregivers to assume it is safe when it is not. This false sense of security is what makes this group particularly at risk; they are looking at a container that appears secure but is actually compromised against their most vulnerable household members. Therefore, the "who" in this context is any child who can reach the bottle, regardless of whether they live in the home or are visiting, as well as any caregiver who relies on the assumption that prescription packaging is inherently safe from tampering.

How to tell if you have the recalled item

Identifying whether your prescription bottles are part of this specific recall requires careful attention to the labels on both the front and the side of the container. Because this issue involves Sandoz brand medications, you will not find a general "Sandoz" warning sticker on the outside. Instead, you must look for specific details printed directly on the bottle’s label. The first step is to confirm that you have one of the two recalled prescription drugs: either Ezetimibe 10mg Tablets or Losartan Potassium 50mg Tablets. These are common medications used to manage cholesterol and high blood pressure, respectively, so having them in your cabinet does not automatically mean they are part of the recall. You must verify the specific National Drug Code (NDC) number and the lot number to be certain.

For those who have been prescribed Ezetimibe 10mg Tablets, check the front label for the NDC number 0781-5690-31, which corresponds to a 30-count bottle, or NDC number 0781-5690-92, which corresponds to a 90-count bottle. If you have Losartan Potassium 50mg Tablets, look for the NDC number 0781-5701-31 on the front label, which indicates a 30-count bottle. Once you have confirmed the medication type and the NDC number, turn the bottle around to inspect the side of the label. This is where the critical lot numbers and expiration dates are printed. A bottle is part of this recall if its lot number matches one of the specific codes listed below along with its corresponding expiration date.

Please review your bottles against the following list carefully. If your lot number appears here, the closure on that bottle may not meet child-resistant safety standards:

• Ezetimibe 10mg Tablets (30-count bottle, NDC 0781-5690-31): Lot numbers JE4491, JE4492, JE4493, and JE4495 with an expiration date of Aug-2020; Lot numbers JG0308, JG0310, JG0311, JG0312, JG5061, and JG5063 with an expiration date of Sep-2020; and Lot numbers JK8921, JK8922, JK8923, JK8924, JL5535, JM2253, JM2254, JM2255, JM2257, JM2258, JM2259, JM5986, and JM5987 with an expiration date of Oct-2020.
• Ezetimibe 10mg Tablets (90-count bottle, NDC 0781-5690-92): Lot numbers JE4481 with an expiration date of Aug-2020; Lot number JG0249 with an expiration date of Sep-2020; Lot number JK8989 with an expiration date of Oct-2020; and Lot number JN0764 with an expiration date of Jan-2021.
• Losartan Potassium 50mg Tablets (30-count bottle, NDC 0781-5701-31): Lot number HV9471 with an expiration date of Feb-2020.

If your bottles do not match these exact NDC and lot number combinations, they are not part of this recall. However, if you find a matching lot number, please do not discard the medication immediately. The recall remedy focuses on securing the bottle, not necessarily discarding the contents right away. You can continue to use the medication as directed once you have taken immediate steps to keep it out of sight and reach of children.

What to do — step by step

Your refund, repair, or replacement options

If you have been affected by this recall, the primary remedy offered is straightforward and designed to ensure your safety without causing unnecessary disruption to your health regimen. Sandoz has committed to providing free replacement child-resistant bottle caps for the affected prescription medication bottles. This specific action addresses the core issue: the original packaging did not meet the mandatory child-resistant closure requirements set by the Poison Prevention Packaging Act. By supplying these specialized caps, the manufacturer aims to restore the necessary safety barrier that prevents young children from accessing the contents of the bottle.

To obtain your free replacement cap, you must contact Sandoz directly. The company has established a dedicated consumer hotline for this purpose, which you can reach at 800-525-8747. It is important to note the specific hours of operation for this line; they are available from 8:30 a.m. to 5 p.m. Eastern Time, Monday through Friday. If you prefer to handle this process online, you may also visit www.us.sandoz.com. Navigate to the “Patients and Customers” section on their website, and then select “Product Safety Notices” to find the relevant information and instructions for requesting your replacement cap.

While securing a new cap is the immediate physical remedy, it is equally important to understand how this affects your use of the medication. Once you have secured the medications by attaching the new child-resistant cap—or by moving them to a safe location out of sight and reach—you are permitted to continue using the medication exactly as directed by your healthcare provider. This recall does not indicate that the medication itself is defective, contaminated, or ineffective. The issue lies solely with the packaging’s inability to prevent child access. Therefore, you do not need to discard the pills or seek a new prescription from your doctor at this stage.

However, there are some limitations to be aware of regarding the scope of this remedy. The recall facts provided do not mention full refunds for the cost of the medication or shipping costs for returning the old bottles. The focus is strictly on providing the safety component—the cap—so that the existing medication can be used safely. If you have questions about whether your specific lot number qualifies for this replacement, or if you encounter any difficulties with the contact process, the phone line and website listed above are your official channels for assistance. Always verify the lot numbers on your bottle against the recall list to ensure you are part of this specific batch before contacting Sandoz.

In summary, your option is to secure the safety closure at no cost through Sandoz’s customer service. This approach allows you to maintain your current treatment plan while addressing the critical safety hazard. By taking these steps, you protect your household from potential poisoning risks without interrupting your health care routine. Remember to keep the medication out of sight and reach of children until you have successfully applied the new cap.

What can happen if you ignore it

It is easy to look at a prescription bottle sitting on a bathroom counter or in a kitchen cabinet and see only a routine part of daily health management. However, ignoring this specific recall carries a serious, immediate risk that goes beyond mere inconvenience. The core issue here is not that the medication itself is defective, expired, or ineffective. The Losartan Potassium and Ezetimibe tablets inside the recalled bottles are safe and effective when taken as directed. The danger lies entirely in the packaging’s failure to meet federal safety standards. Because the closure mechanism does not function as a child-resistant barrier, the bottle offers no meaningful protection against curious hands or determined toddlers who might mistake the colorful pills for candy.

If you continue to use these bottles without taking action, you are leaving your home vulnerable to accidental pediatric poisoning. Children are naturally exploratory; they learn about the world by touching and tasting. A standard prescription bottle cap that requires significant force, dexterity, or specific coordination to open is designed precisely to prevent this. When that barrier is compromised, a young child can open the bottle with ease. Once opened, the contents are accessible. Ingesting even a small amount of these medications can lead to severe health consequences. For a child, who has a much lower body weight than an adult, the dosage required to cause harm is significantly smaller. Accidental ingestion could result in symptoms ranging from dizziness and lethargy to more critical cardiovascular events, depending on the amount consumed and the individual’s reaction.

While the official recall notice from the Consumer Product Safety Commission (CPSC) states that there are currently no reported incidents of injury or poisoning related to this specific batch of bottles, this absence of data should not be interpreted as safety. The lack of reported cases is often because these events have not yet occurred, not because the risk is negligible. Relying on the hope that nothing will happen is a dangerous gamble when the potential outcome involves a child’s life or long-term health. The hazard is latent and passive; it sits quietly in your home until an opportunity arises for a child to interact with it. Once that interaction happens, the consequences are irreversible in the moment.

Furthermore, ignoring the recall means missing out on a simple, free remedy that eliminates this risk entirely. By doing nothing, you accept the possibility of a medical emergency. In the event of an accidental ingestion, the result would likely be a frantic trip to the emergency room, urgent calls to poison control, and unnecessary stress for your entire family. The anxiety of wondering if a child has taken medication can linger long after the immediate danger has passed. By securing the medication and obtaining the free replacement caps, you remove this variable from your life. You transform a potential crisis into a non-event. The effort required is minimal compared to the profound peace of mind that comes from knowing your home is truly safe for young children. Do not wait for an accident to validate the importance of these safety standards; act now to ensure they remain just that—standards, not warnings.

Staying safe: broader tips